Journey Medical (DERM) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to -$2.3 million.
- Journey Medical's Net Income towards Common Stockholders rose 313.81% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year increase of 5308.68%. This contributed to the annual value of -$14.7 million for FY2024, which is 28079.42% down from last year.
- Journey Medical's Net Income towards Common Stockholders amounted to -$2.3 million in Q3 2025, which was up 313.81% from -$3.8 million recorded in Q2 2025.
- In the past 5 years, Journey Medical's Net Income towards Common Stockholders ranged from a high of $16.8 million in Q3 2023 and a low of -$21.8 million during Q4 2021
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$4.1 million (2025), whereas its average is -$5.4 million.
- Per our database at Business Quant, Journey Medical's Net Income towards Common Stockholders plummeted by 3681034.48% in 2021 and then skyrocketed by 26655.75% in 2023.
- Journey Medical's Net Income towards Common Stockholders (Quarter) stood at -$21.8 million in 2021, then soared by 51.07% to -$10.6 million in 2022, then skyrocketed by 79.86% to -$2.1 million in 2023, then surged by 173.82% to $1.6 million in 2024, then tumbled by 246.33% to -$2.3 million in 2025.
- Its last three reported values are -$2.3 million in Q3 2025, -$3.8 million for Q2 2025, and -$4.1 million during Q1 2025.